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ABSTRACT

This invention provides a novel method for purifying syn
thetic oligomers comprising capping, polymerizing and sepa
rating any failure sequences produced during oligomer syn
thesis. Either the failure sequence or the full-length oligomer
may be polymerized. Optionally, small molecule impurities
may also be incorporated into the polymerized material. The
invention provides novel capping agents having a polymeriz
able functional group. The invention also provides kits com
prising at least one composition of the present invention.
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PURIFICATION OF SYNTHETIC
OLIGOMERS

FIG. 3 represents the chemical reaction for formation of
polyacrylamide gel.
FIG. 4 represents the chemical reaction for synthesis of the
capping agents 22-24.
FIG. 5 illustrated the structures of full length sequence and
failure sequences when using 22-24 as capping agents.
FIG. 6 represents the chemical reaction for formation of
disulfide polymer.
FIG. 7 represents the chemical reaction for synthesis of
capping agents 39 and 40.
FIG. 8 represents the chemical reaction for synthesis of
copolymerization agents 44 and 45.
FIG. 9 represents the chemical reaction for synthesis of
capping agents 50 and 51.
FIG. 10 represents the chemical reaction for synthesis of
copolymerization agents 55 and 56.
FIG. 11 represents the Sharpless “click” reaction.
FIG. 12 represents the chemical reaction for synthesis of
capping agents 57-60.
FIG. 13 represents the chemical reaction for synthesis of
copolymerization agents 65 and 66.
FIG. 14 represents the water soluble Grubbs’ ROMP cata
lysts.
FIG. 15 represents the Grubbs’ ROMP reaction.
FIG. 16 represents the chemical reaction for synthesis of
capping agents 74-77, and the copolymerization agents 78
and 79.
FIG. 17 represents the conjugate addition reaction between
maleimide and thiol.
FIG. 18 represents the chemical reaction for synthesis of
capping agents 82 and 83, and the copolymerization agents 55
and 56, and 84, 85 and 86.
FIG. 19 represents the chemical reaction for synthesis of
phosphoramidites 92 and 95.
FIG. 20 represents the full length oligonucleotides after
deprotection and cleavage using phosphoramidites 92 and95.
FIG. 21 represents the chemical reaction of cleavage of
DNAs 98 and 100 from polymer.
FIG. 22 represents the chemical reaction for synthesis of
phosphoramidites 103 and 105.
FIG. 23 represents the structures of the oligonucleotides
after deprotection and cleavage, using 103 or 105 as the
phosphoramidite in the last synthetic cycle in oligonucleotide
synthesis.
FIG. 24 represents the chemical reaction for the cleavage of
DNAs 98 and 100 from polymer.
FIG. 25 represents the chemical reaction for synthesis of
phosphoramidites 113 and 115.
FIG. 26 are the structures of the oligonucleotides after
deprotection and cleavage, using 113 or 115 as phosphora
midite in the last synthetic cycle in oligonucleotide synthesis.
FIG. 27 represents the chemical reaction for cleavage of
DNAs 98 and 100 from polymer.
FIG. 28 represents the chemical reaction for synthesis of
phosphoramidites 122 and 124.
FIG. 29 represents the structures of the oligonucleotides
after deprotection and cleavage, using 122 or 124 as phos
phoramidite in the last synthetic cycle in oligonucleotide
synthesis.
FIG. 30 represents the chemical reaction for cleavage of
DNAs 98 and 100 from polymer.
FIG. 31 represents the chemical reaction for synthesis of
phosphoramidites 132 and 134.
FIG. 32 represents the chemical structures for the oligo
nucleotides after deprotection and cleavage, using 132 or 134
as phosphoramidite in the last synthetic cycle in oligonucle
otide synthesis.
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This application claims priority under 35 U.S.C. §119(e)to
U.S. Provisional Patent Application No. 60/827,592 filed
Sep. 29, 2006, which is hereby incorporated by reference.
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INTRODUCTION
Synthetic oligonucleotides have wide applications in biol
ogy and medicine. With one oligonucleotide drug on the
market and more than 40 others in various stages of clinical
trials, the interest in using oligonucleotides as therapeutic
agents continues to grow. This growing demand requires
large quantities of oligonucleotides. For many purposes,
including use as therapeutic agents to cure human diseases,
these crude oligonucleotides must be purified to remove the
failure sequences generated in the coupling steps in the syn
thesis. Currently used purification methods include gel elec
trophoresis, HPLC and others—all of which are expensive,
labor intensive and unsuitable for large scale purification. The
most frequently used purification methods such as gel elec
trophoresis are not suitable for large scale purification.
Reverse phase and ion exchange HPLC have been adapted to
large scale purification, but there are high costs associated
with instrumentation, eluents (including their evaporation)
and columns. Other known purification methods are also not
ideal. Consequently, the development of highly efficient and
low cost methods for large scale production of oligonucle
otides is desired.
SUMMARY OF THE INVENTION
The present invention provides a method of purifying oli
gomers comprising capping any failure sequences produced
during synthesis with a capping agent having a polymerizable
functional group, polymerizing the capped failure sequences;
and separating the polymerized material from the full-length
oligomer.
The present invention also provides a method of purifying
an oligomer comprising attaching a polymerizable functional
group to an end of a full length oligomer, polymerizing the
full length oligomers, removing the failure sequences from
the polymerized full length oligomers, and recovering the full
length oligomers.
In addition, the present invention provides capping agents
comprising polymerizable functional groups and its for puri
fying oligomers.
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BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 illustrates one method for oligonucleotide purifica
tion. Unwanted failure sequences contain polymerizable
function, while the desired full length sequences do not. After
polymerization, failure sequences are incorporated into a
polymer, and full length sequences are isolated by simple
extraction.
FIG. 2 illustrates an additional method for oligonucleotide
purification. Desired full length sequences contain polymer
izable function, while unwanted sequences do not. After
polymerization, full length sequences are incorporated into a
polymer, failure sequences are removed by washing, and full
length sequences are cleaved from the polymer and extracted
with a buffer.

55
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FIG. 33 represents the chemical reaction forthe cleavage of
DNAs 98 and 100 from polymer.
FIG. 34 represents the chemical reaction for the synthesis
of capping agent 141.
FIG. 35 represents the chemical reaction for the synthesis
of phosphoramidites 150.

mers such as peptide nucleic acid conjugates and glycopeptides. Modified oligomers include peptide nucleic acids,
locked DNA, phosphotihioate oligonucleotides, beta-peptides and quaternary peptides. Modifications to oligosaccha
rides include alterations of ring size, ring atoms and various
substitutions on the sugar rings. One of ordinary skill in the art
can envision other modified oligomers which fall within the
scope of the present invention. Oligomers may contain both
natural and unnatural monomers. For example, both D- and
L-amino acids can be used. The term “oligomer” is not
intended to be limited to any specific number of monomers.
Instead, it is meant to encompass an oligomer (or polymer) of
any length that can be made by a step-wise process.
As used herein, “failure sequence” means an oligomer to
which the next monomer did not attach during synthesis.
Thus, a failure sequence of any given step in the synthesis
contains all monomers except for the most recently added
monomer.
As used herein, “lower alkyl” means an alkyl group of 1 to
4 carbon atoms, that may be branched, such as methyl, ethyl,
propyl, isopropyl and butyl.
The oligomer purification methods of the present invention
are suitable for both laige and small scale purification. Oli
gomers purified by the methods of the present invention are
substantially free of failure sequences and have similar or
better qualify than those purified by DMTr-on reverse phase
HPLC method. The purified oligomer may be of greater than
about 90% purify, or greater than about 95%, or greater than
about 97%, or greater than about 99% or greater than about
99.5%. By “substantially free”, it is meant that the oligomer
contains less than about 5% by weight of failure sequences, or
less than about 3%, or less than about 1% or less than about
0.5%.
In one embodiment of the present invention, simple phos
phorous compounds that contain functional groups capable of
polymerizing in the presence of an initiator and/or a polymer
ization partner are used as capping agents (in place of the
commonly used acetic anhydride) during oligomer synthesis
to block failure sequences. Thus, all unwanted failure
sequences contain the polymerizable functions, while the
desired full length sequences do not. After synthesis, failure
sequences are incorporated into a polymerized material, and
the full length oligomers remain in solution or in the polymer
matrix and are separated from the polymerized material using
any technique known to one of ordinary skill in the art includ
ing extraction with buffer and filtration. If the oligomer is
synthesized on a solid support, the oligomer can be cleaved
from the solid support prior to polymerization. (See FIG. 1).
In another embodiment of the present invention, polymer
izable functional groups are incorporated onto the end of the
full length sequences in the last step of oligomer synthesis.
Because failure sequences are capped with a standard cap
ping agent, such as acetic anhydride, dimethyl-formanide,
diethylene glycol monoethyl ether phosphoramidite, or b is(l,
l,l,3,3,3-hexafluoro-2-propyl)-2-propyl phosphate, in each
synthetic cycle, only the full length sequence contains the
polymerizable functional group. Once the full length
sequences are incorporated into a polymerized material, the
failure sequences are removed by simple washing because
they do not contain a polymerizable functional group, and
then, full length sequences are recovered from the polymer
ized material using a cleavage reagent. (See FIG. 2). If the
synthesis occurs on a solid support, the oligomer can be
cleaved from the solid support before or after polymerization.
Using either of these methods, the small molecules resulted
from deprotection of nucleobases and phosphate groups can
also be removed if suitable polymerizable functions are incor
porated into the protecting groups. When the first method is
used, the small molecules resulted from deprotection will be
incorporated into the polymerized material in the same fash
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DETAILED DESCRIPTION OF THE INVENTION
The present invention includes a method of purifying syn
thetic oligomers via a polymerization technique, capping
agents having a polymerizable functional group, and kits for
purifying oligomers comprising a capping agent having polyerizable functional group. Synthesis of oligomers generally
proceeds in a step-wise manner with each monomer being
added in sequence to the ends of a plurality growing oligomer.
After synthesis and deprotection/cleavage, crude oligomers
normally contains the following impurities:
(i) Truncated failure sequences. These impurities result
from the coupling steps of the synthesis. For a successful
20-mer synthesis, these impurities comprise about 30% of the
oligonucleotide content of the crude mixture. They have simi
lar physical properties as the desired full length sequences,
and so are difficult to remove. They are usually capped with
acetic anhydride in the synthesis. As a result, if the 5'-OH
DMTr (4,4'-dimethoxytrifyl) protecting groups in the last
synthesis cycle are not removed, then after basic deprotection
and cleavage, the full length sequences have the hydrophobic
DMTr group on their 5'-end while the failure sequences do
not (acyl groups on the failure sequences are removed under
deprotection conditions). This is the basis of DMTr-on
reverse phase HPLC purification. Although this is the most
widely used oligonucleotide purification method, it is very
costly for large scale production.
(ii) Small organic impurities. These result from the phos
phate and exo-amino protecting groups which include acry
lonitrile, benzamide, acetamide and isobutyramide and others
depending on which protecting groups are used. Because of
their very different physical properties from oligonucle
otides, they can be removed by precipitation from aqueous
buffer with ethanol or 2-propanol.
(iii) Other oligonucleotide impurities. These are very dif
ficult to remove; fortunately, only very limited quantities are
typically present. Two examples are N +l and N+2 sequences,
which result from double coupling due to the mild acidity of
activating agents that causes premature detritylation in the
coupling step. They can be troublesome to remove even on
small scale. When the DMTr-on reverse phase HPLC strategy
is used, they also contain a 5'-DMTr group. Ion exchange
HPLC cannot resolve a single nucleotide difference for a
typical 20-mer. Gel electrophoresis can do the job but can
only on a very small scale. Additional impurities are acryloni
trile-oligonucleotide adducts. In addition, for oligophosphorothioate synthesis, because of incomplete sulffirization,
impurities such as (? = ())! and ( P = 0 ) 2 mers exist, they can
be kept to a minimum amount by using a more efficient
sulffirization agent.
These impurities need to be separated from the desired
full-length oligomer when synthesis is complete. The present
invention contemplates the purification of oligomers through
the use of capping agents containing polymerizable func
tional groups. Both failure sequences and small organic
impurities can be removed using the method of the present
invention.
As used herein, “oligomer” includes oligonucleotides,
modified oligonucleotides, polynucleotides, modified poly
nucleotides, oligosaccharides, modified oligosaccharides,
polysaccharides, modified polysaccarides, peptides, modi
fied peptides, polypeptides, modified polypeptides, and any
conjugates of two or more of these different types of oligo
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ion as the failure sequences are incorporated. When the sec
ond method is used, the small molecules resulted from depro
tection will also be incorporated into the polymerized
material. However, the full length sequence can be cleaved
from the polymerized material and the small molecule impu
rities cannot because there is no cleavable linker in them.
Polymerization reactions suitable for the methods of the
present invention have one or more of the following charac
teristics: (i) the polymerization reaction is highly efficient
once initiated; (ii) the reaction tolerates moisture and air and,
suitably, can be performed in aqueous buffer; (iii) oligomers
are stable under the polymerization conditions; and (iv) the
polymerizable functional groups are easily accessible and are
stable under oligomer synthesis conditions.
Reactions that are suitable for oligonucleotide purification
include, but are not limited to, the radical acrylamide poly
merization reaction, the thiol oxidation to disulfide reaction,
the Sharpless “click” reaction, the Grubbs aqueous ROMP
reaction, the conjugate addition reaction between maleimide
and thiol, and the amide bond formation reaction between
carboxylic acid esters and alkyl amines. Reactions that are
suitable for oligosaccharide and peptide purification include,
but are not limited to, the Sharpless “click” reaction.

R9 is an electron withdrawing group such as cyano,
COOR10, S 0 2Ph and N 0 2;
R10 is lower alkyl; and
at least one R2 is

Radical Acrylamide Polymerization
The general acrylamide polymerization reaction is shown
in FIG. 3. The materials for this reaction are inexpensive, and
the reaction is highly efficient and can be performed in aque
ous buffer open to air at room temperature. In addition, acry
lamide functionalities are stable under oligonucleotide syn
thesis and deprotection/cleavage conditions using
phosphoramidite chemistry. Appropriate polymerization
conditions can be readily determined by one of ordinary skill
in the art. Suitable conditions include (NH4)2S20 8/TMEDA/
water at room temperature for about 1 hour. For example, for
a 1 mmol oligonucleotide synthesis, optionally about 10
mmol to about 100 mmol acrylamide, optionally about 0.2
mmol to about 2.0 mmol N,N'-methylene-bisacrylamide,
about 1 pmol to about 10 tpmol (NH4)2S20 8, and about 1
pmol to about 10 pmol TMDEA may be used.
Suitable capping agents for purification using radical acry
lamide polymerization include compounds of formula (I):

5
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Suitably, the capping agent contains more than one polymer
izable functional group. It is hypothesized that additional
polymerizable functional groups on the capping agent
increase the likelihood that capped polymers will be incorpo
rated into the polymer.
However, capping agents containing only one polymeriz
able functional group have the advantage of more stable under
basic deprotection/cleavage conditions when the other R2 is a
removable group such as 2-cyanoethyl group.
When R2 is a secondary amino group, the capping agents
for radical acrylamide polymerization require the use of an
activating agent. The most commonly used activating agent is
lH-tetrazole. Other suitable activating agents include, but are
not limited to 4,5-dicyanoimidazole, 5-(4-nitrophenyl)-lHtetrazole, 5-methylthio-lH-tetrazole, 5-ethylthio-lH-tetrazole, ethylthiotetrazole, and 5-benzylmereapto-lH-tetrazole.
Optionally, when R2 is a halogen atom, a base may be
added to neutralize acid produced during the capping reac
tion. The base may be an amine base such as trimethylamine,
pyridine, diazobicyclo base, or 5-methoxybenzimidazole.
Syntheses of suitable phosphorous capping agents 22-24
(shown below) are shown in FIG. 4.

35
22

40

45

wherein R2 is halogen, such as Cl, Br, or F or a secondary
amine group, such as

50

H

Rio
----- N

55

\

Rio;

R2 is independently selected from lower alkyl,
60

65

n is an integer from 1 to 5;

Compounds 22 and 23 contain two polymerizable func
tional groups, which can increase the likelihood that failure
sequences will be incorporated into the polymer. Compound
24 contains only one polymerizable functional group. When
compound 22 is used for capping, an activator is required. If
23 or 24 is used, no activating agent is required, but an amine
base, such as trimethylamine, pyridine, diazobicyclo base, or
5 -methoxybenzimidazole, must be used to neutralize the acid
generated.
Because there is less concern about premature detritylation
in capping steps than in coupling steps, other capping agents
such as ammonium salts developed by Beaucage, Caruthers
and Wada and co-workers can be used.
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For purification of oligomers using polyacrylamide forma
tion reaction, an alternative procedure is to use a fluoride
cleavable linker to attach the growing oligomers to the solid
support (instead of using the more common base cleavable
linkers; besides fluoride cleavable linkers, other non-base
cleavable linker such as photo cleavable linkers can also be
used) for oligomer synthesis. After synthesis, the oligomers
are cleaved from the solid support by treating with fluoride.
The crude un-deprotected oligomers are subjected to poly
merization reaction conditions. The failure sequences are
incorporated into a polymerized material and the full length
sequences remain in solution or in polymer matrix. After
removal of failure sequences by filtration and extraction of the
full length sequences from polymer matrix, the full length
sequences are subjected to base de-protection conditions and
further purified by recrystallization to remove small mol
ecules resulted from de-deprotection. This alternative purifi
cation procedure avoids the possibility of adding nucleo
philes to acrylamide functionalities in the base de-protection
steps.

R9 is an electron withdrawing group such as cyano,
COOR10, S 0 2Ph and N 0 2; and
R10 is lower alkyl.
Suitable copolymerization agents include compounds of
formula (III):

Formation of Disulfide Polymer
Thiols may be oxidized to form polymers. One of ordinary
skill in the art can determine polymerization conditions that
are suitable for such polymerization. For example, for a 1
mmol oligonucleotide synthesis, about 10 mmol to about 100
mmol of a copolymerization agent and about 0.2 mmol to
about 2 mmol of a cross-linking copolymerization agent that
contains more than 2 thiols in one molecule such as 45 and 56
can be used. Suitably, the mixture is heated in dimethylsulfoxide, for example, to about 90° C. If dimethylsulfoxide is
used as a solvent, no additional oxidizing agent is necessary.
If another solvent is used, then an oxidizing agent, such as
oxygen or others known to those skilled in the art should be
added.
Suitable capping agents for purification using formation of
a disulfide polymer include compounds of formula (I):

5
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20
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40
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or3

wherein R3 is halogen, such as Cl, Br or F or a secondary
amine, such as
45

^Rio
----- N
\

Rio;

50

R3 is independently selected from lower alkyl or
55

60

65

n is an integer from 1 to 5;
m is an integer from 0 to 4;

wherein n is an integer from 1 to 5;
q is independently an integer from 0 to 3; and
r is independently an integer from 1 to 2. Suitably, if r is 1
then the thiol group is at the para-position; if r is 2 then the
thiol groups are at the meta-positions.
Thiols 39, 40, 50 and 51 (shown below) are exemplary
capping agents for this reaction.
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10
(IV)
5

10 wherein R2 is a halogen, such as Cl, Br or F or a secondary
amine, such as

Rio
15

Thiols 44, 45, 55 and 56 (shown below) are exemplary
copolymerization agents for this reaction.

44 20

R4 is

The Sharpless “Click” Reaction
The Sharpless “click” reaction is a highly reliable reaction
(FIG. 11) and can be performed under aqueous mild condi- 55
tions. The reaction partners—the terminal alkyne and the
alkylazide—are readily accessible stable functional groups.
The mild reaction conditions are compatible with many func
tional groups including those in oligonucleotides. One of
ordinary skill in the art can readily determine suitable reac- 60
wherein Rs is
tion conditions. For example, for a 1 mmol oligonucleotide
synthesis, one can use about 10 mmol to about 100 mmol of
each of the copolymerization agents, about 0.05 mmol to
about 5.0 mmol C uS04 and about 0.05 mmol to about 5.0
mmol sodium ascorbate.
65
Suitable capping agents for purification using the Sharp
less “click” reaction include compounds of formula (IV)

(VI)

US 7,850,949 B2
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Grubbs’ ROMP Reaction
The ring opening metathesis polymerization (ROMP)
t is an integer from 1 to 3;
15 reaction is also useful for oligonucleotide purification. The
polymerization reaction can be performed in aqueous solu
R9 is an electron withdrawing group such as cyano, COOR10,
tion using water soluble catalysts (67-69, FIG. 14), and the
S 0 2Ph and N 0 2;
reaction tolerates a wide range of functional groups. One of
R10 is lower alkyl
ordinary skill in the art can readily determine suitable poly
merization
conditions. Forexample, fora 1 mmol oligonucle
Alkynes 57-60 (shown below) are exemplary capping
otide synthesis, one can use about 10 mmol to about 100
agents for this reaction.
mmol of a copolymerization agent, about 0.02 mmol to about
2.0 mmol cross-linking copolymerization agent that contains
25 more than one alkene function such as 78 and 79, and about
57
0.01 mmol to about 1.0 mmol metathesis catalyst.
The substrates for polymerization can be those such as 70
and 71 as shown in FIG. 15. Suitable catalysts for the ROMP
purification include, but are not limited to, catalyst 69. After
30 polymerization, the catalyst may be removed by extraction
with organic solvents such as CF12C12.
The capping agent is suitably a compound of formula
58
(VII):
n is independently an integer from 1 to 5,

35

(VII)

Ri
I
R6c r

40
59

wherein Rj is halogen, such as Cl, Br or F or a secondary

R6is
Compounds 65 and 66 are exemplary copolymerization
agents.

X is independently O or CF12;
R9 is an electron withdrawing group such as cyano,
COOR10, S 0 2Ph and N 0 2;
R10 is lower alkyl; and
n is independently an integer from 1 to 5.

US 7,850,949 B2
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A suitable copolymerization agent is a compound of for
mula (VII)
o

II

RgO— P — ORg

ization agent and about 0.2 mmol to about 2.0 mmol of a
cross-linking thiol that contains more than 2 thiols in one
molecule such as 56 and 86 in a suitable buffer such as
(VIII)
phosphate buffered saline buffers and at a suitable tempera5 ture such as room temperature and 60° C. Suitable capping
reagents are compounds of formula (IX)

OH

(IX)

wherein R6 is
10

wherein R 2 is halogen, such as Cl, Br or F or a secondary
amine, such as
X is independently O or CH2; and
n is independently an integer from 1 to 5.
Compounds 74-77 are exemplary capping agents.

74, X = O
75, X = CH2

R9 is an electron withdrawing group such as cyano,
COOR10, S 0 2Ph and N 0 2;
R10 is lower alkyl; and
n is independently an integer from 1 to 5.
One of the R7 may also be any functionality that contains 2
or more a,p-unsaturated carbonyl functions
Suitable copolymerization agents include compounds of
formula (III):

76, X = O
77, X = CH2

Compounds 78, 79, 139, and 140 are exemplary copoly
merization agents.
40

45

139, X
140, X

wherein n is an integer from 1 to 5;
q is independently an integer from 0 to 3; and
r is independently an integer from 1 to 2. Suitably, if r is 1
then the thiol group is at the para-position; if r is 2 then the
thiol groups are at the meta-positions,
or a compound o f formula (X):

0 , n = 1-5
CH2, n = 1-5

Conjugate Addition Reaction Between Maleimide and Thiol
The conjugate addition reaction between maleimide and
thiol (FIG. 25) is widely used in bioconjugate chemistry. This
reaction can be performed in different aqueous buffers in a
relatively wide range of pFl values (6.5-9) at room tempera
ture, and the reaction is known to be compatible with oligo
nucleotides. One of ordinary skill in the art can readily deter
mine suitable reaction conditions. For example, for a 1 mmol
oligonucleotide synthesis, one can use about 10 mmol to
about 100 mmol of a bis-thiol copolymerization agent, about
10 mmol to about 100 mmol of a bis-maleimide copolymer-

60
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wherein n is an integer from 1 to 5 or a compound of
formula (XI):
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-continued
84

(XI)
5

85

wherein q is an integer from 0 to 3; and
t is independently an integer from 1 to 3. Suitably, if t is 2
then the thiol groups are para to each other; if t is 3 then the
thiol groups are in the meta-positions.

86

Compounds 82 and 83 are exemplary capping agents.

Amide Formation Between an Ester and an Amine
Amines can react with carboxylic acid derivatives to form
amides. This reaction can also be used as the polymerization
reaction for purification of oligomers that are synthesized
step-wise. One possible such polymerization reaction is
shown here:

Compounds 55, 56, 84, 85 and 86 are exemplary copoly
merization agents.
40
55

O

O

wherein R12 is a suitable leaving group, such as CF13,
CH2CH3, CH2CH2OCH3, CH2CH2OPh, or OPh;
Rn is selected from hydrogen or lower alkyl3;
a is an integer from 1 to 6; and
b is an undetermined integer.

65

When using such polymerization reactions to purify oligo
mers, a suitable condition for a 1 mmol oligomer synthesis, is:
about 10 mmol to about 100 mmol of a copolymerization
agent and about 0.2 mmol to about 2 mmol of a cross-linking
copolymerization agent. The oligonucleotides do not need to
be deprotected/cleaved prior to polymerization. The oligo
nucleotides on solid support can be treated directly under
these polymerization conditions. The oligonucleotides will
be deprotected/cleaved by the amino group in the copolymer
ization monomer. The advantages of this method include
incorporation of both failure sequences and small molecules
resulted from deprotection such as acetyl amide into the poly
mer and no need for separate deprotection and cleavage step.
Suitable capping agents for purification using the amide
bond formation reaction for polymerization includes com
pounds of formula (XU):

US 7,850,949 B2
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18
Compounds 141,142,143, and 144 are exemplary capping
agents for this reaction:

5
R 130

o r 13

wherein Rj is halogen, such as Cl, Br or F or a secondary
amine such as
10

^Rio
----- N
\

Rio,

15

R13 may be

O

20

wherein R9 is an electron withdrawing group such as cyano,
COOR10, S 0 2Ph and N 0 2;

25

R10 is lower alkyl;
R12 is a suitable leaving group, such as CF13, CF12CF[3,
CH2CH2OCH3, CH2CH2OPh, or OPh; and
a is an integer from 1 to 6.
One of the R12 groups may also be any functionality that
contains 2 or more ester groups.
Suitable copolymerization reagents include but are not
limited to

30

Compounds 145,146,147,148 are exemplary copolymer
ization agents for this reaction:
35

40

wherein R12 is a suitable leaving group, such as CF13,
CH2CH3, CH2CH2OCH3, CH2CH2OPh, or OPh;
Rn is selected from the group consisting of hydrogen or
lower alkyl;

45

Y = 0 or S; and
a is an integer from 1 to 6.
Suitable cross-linking copolymerization agents include but
are not limited to:

50

Compound 149 is an exemplary cross-linking copolymer
ization agent for this reaction:
55

60
N HRn

N HRn

wherein R12 is a suitable leaving group, such as CF13,
CH2CH3, CH2CH2OCH3, CH2CH2OPH, or OPh;
Rj j is selected from the group consisting of hydrogen and
lower alkyl;

65
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Polymerization of Full Length Oligomer
In another embodiment of the present invention, the poly
merization reactions can be used to polymerize the desired
full-length oligomer sequence. In this embodiment, the cap
ping agent is the normal acetic anhydride or any other suitable
capping agent, but at the end of solid phase synthesis, a
phosphoramidite that contains a suitable polymerizable func
tional group is coupled to the end of the oligomer through a
cleavable linker. Because failure sequences are all capped
with acetic anhydride in each synthetic cycle, only the full

length sequence contains the polymerizable functional group.
After synthesis, deprotection and cleavage, the crude oligo
mer is subjected to polymerization; the full length sequence is
incorporated into the polymerized material while failure
sequences and other impurities remain in solution, which can
be removed by filtration or extraction with a buffer. The pure
full length sequences are then cleaved from the polymerized
material and extracted with a buffer.
Suitable phosphoramidites include compounds 92, 95,
103, 105, 113,115,122, 124, 132, 134, 150,151:

5
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-continued
132

o

Polymerization of Small Molecule Impurities
In yet another embodiment of the present invention, small 55
molecule impurities can be incorporated into the polymerized
material and removed along with the failure sequences. In this
embodiment, the protecting groups contain a polymerizable
functional group, and are also incorporated into the polymerized material. Here, the Sharpless “click” reaction is used as
example.
The oligomer is synthesized under standard conditions.
However the protecting groups for the nucleobases and the g5
phosphate groups contain a polymerizable functional group.
The following phosphoramidite monomers are exemplary:

US 7,850,949 B2
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-continued

tional capping agent, such as acetic anhydride and one of the
phosphoramidites shown below can be used in the last syn
thetic cycle.
5

o

DMTiO
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DMTrO
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DMTiO

40

45

50

DMTr

55

60

If failure sequences are capped with agents such as 57-60,
after cleavage/deprotection, the failure sequence and the
small molecules resulted from the protecting groups will all
be incorporated into the polymerized material. The full length
sequence can be obtained by filtration and extraction. Alter
natively, the failure sequences can be capped with a tradi-

65
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5

After synthesis and cleavage/deprotection, the full length
sequence and the small molecule impurities resulting from
protecting groups are incorporated into the polymerized
material upon initiation of the polymerization reaction. The
failure sequences can be removed by washing. The full length
sequences (not small molecules resulted from protecting
groups) are then cleaved from the polymer and extracted with
buffer.
Kits for Purifying Oligomers
A further embodiment of the present invention is a kit
comprising either a capping agent having a polymerizable
functional group or a compound having a polymerizable
functional group for attaching to the end of the full length
oligomer. Kits can further comprise monomers, coupling
reagents, polymerization reagents, buffers, cleavage agents,
and other components necessary to synthesize and purify an
oligomer in accordance with the present invention.
As used in this specification and the appended claims, the
singular forms “a,” “an,” and “the” include plural referents
unless the content clearly dictates otherwise. It should also be
noted that the term “or” is generally employed in its sense
including “and/or” unless the content clearly dictates other
wise. All publications, patents and patent applications refer
enced in this specification are indicative of the level of ordi
nary skill in the art to which this invention pertains. All
publications, patents and patent applications are herein
expressly incorporated by reference to the same extent as if
each individual publication or patent application was specifi
cally and individually indicated by reference. In case of con
flict between the present disclosure and the incorporated pat
ents, publications and references, the present disclosure
should control.
It also is specifically understood that any numerical range
recited herein includes all values from the lower value to the
upper value, i.e., all possible combinations of numerical val
ues between the lowest value and the highest value enumer
ated are to be considered to be expressly stated in this appli
cation. For example, if a concentration range is stated as 1%
to 50%, it is intended that values such as 2% to 40%, 10% to
30%, or 1% to 3%, etc., are expressly enumerated in this
specification.
The following examples are provided to assist in a further
understanding of the invention. The particular materials,
methods and conditions employed are intended to be illustra
tive of the invention and are not limiting upon the scope of the
invention.
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Example 2
Synthesis of Thiol Capping Agents and Purification
Using Disulfide Formation of Failure Sequences

25

30

35

40

45
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As shown in FIG. 7, 34 is converted to 36 using 35, and
acetylated to give 37. Then 37 is converted to 39 or 40 using
similar procedures for preparing 22-24. Alternatively, 37 can
be synthesized from 41 in one pot as shown in FIG. 7. The
thiols 44 and 45, which are required for copolymerization,
can also be readily synthesized (FIG. 8).
After synthesis and deprotection/cleavage, the crude oli
gonucleotide is subjected to polymerization conditions in the
presence of 44 and 45 mentioned above. Full length oligo
nucleotides are collected by filtration and/or extraction. Small
organic impurities can be removed by precipitation.
Alternatively, thiols 50 and 51 can be used for capping
failure sequences, and 55 and 56 can be used as copolymer
ization agents. Their syntheses are illustrated in FIGS. 9 and
10. Compound 48 is prepared from 46 and NBS followed by
reacting with AcS- under basic conditions (FIG. 9), which is
then converted to the capping agents 50 and 51 using the
above described conditions. The copolymerization agents 55
and 56 are readily available as shown in FIG. 10 from com
pounds 52 and 48. The oligonucleotide synthesis, capping
failure sequences with 39, 40, 50 or 51, deprotection/cleav
age, polymerization in the presence with 44 and 45 or 55 and
56, purification and analysis of purification results are the
same as previously described.
Example 3

55

EXAMPLES
Example 1
60

Purification Via Radical Acrylamide Polymerization
of Failure Sequences
After synthesis, the oligonucleotide 25 is cleaved and
deprotected under standard basic conditions (for example,
K2C 0 3, anhydrous methanol, room temperature, 24 hours
and concentrated ammonium hydroxide, 60° C.). The crude

oligonucleotides are subjected to polymerization conditions,
e.g. (NFl4)2S20 8/TMEDA/water/r.t./l h, to incorporate the
failure sequences into polymer. The full length sequence 25
(FIG. 5) remains in solution or in the polymer matrix because
it does not contain an acrylamide function. Collection of the
full length sequence can be achieved by filtration and/or
extraction from the polymer gel using a buffer. Impurities
resulting from the protecting groups in the synthesis such as
acrylonitrile benzamide, acetamide and isobutyramide can be
removed by first dissolving the material in sodium acetate
buffer and then precipitating the oligonucleotide with 2-propanol (for less than 15 -mer) or ethanol (for more than 15 -mer)
at -10° C. The small organic impurities remain in solution.
Alternatively, protecting groups containing acrylamide func
tions can be used so that all small organic impurities can be
removed by polymerization.

65

Synthesis of Capping Agents and Purification via
Sharpless “Click” Polymerization of Failure
Sequences
The capping agents that contain terminal alkynes (57-60)
can be easily synthesized according to FIG. 12 from 61 and
62. The polymerization partner 65 is prepared by reacting 63
with 3-bromo-1 -propanol to give 64, followed by treating
with sodium azide (FIG. 13). The other copolymerization
partner 66 is prepared similarly from propargyl alcohol 61
and 63 (FIG. 13). The oligonucleotide synthesis, capping
failure sequences with 57-60, deprotection/cleavage, poly
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merization in the presence of 65 and 66, purification and
analysis of purification results are the same as above.

sequence remains in solution or in polymer matrix. Filtration
and extraction provide pure full-length sequence.
Example 7

Example 4
5

Synthesis of Phosphoramidites 92 and 95 and
Purification Via Radical Acrylamide Polymerization
of Full-Length Oligomers

Synthesis of Capping Agents for Purification Via
Grubb’s Ring Opening Metathasis Polymerization of
Failure Sequences
The synthesis of the capping agents 74-77 is shown in FIG.
16. Compounds 72 and 73 can be synthesized from 70 (this
compound can be prepared readily by stirring the solution of
maleic anhydride and furan in ether at room temperature for
12 hours; the exo isomer is formed exclusively as a white
precipitate) and 71 (both are commercially available and can
be prepared using known procedures) by heating with
3-amino-l -propanol under vacuum in high yields. These two
compounds are then converted to the capping agents 74-77
under conditions described above. Suitably, the exo isomers
of these compounds are used. The water soluble copolymer
ization monomers 78 and 79 can be synthesized similarly
(FIG. 16). The oligonucleotide synthesis, capping failure
sequences with 74-77, deprotection/cleavage, polymeriza
tion in the presence of 78 or 79, purification and analysis of
purification results are the same as described.
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Example 5
Synthesis of Capping Agents and Purification Via
Conjugate Addition of Maleimide and Thiol of
Failure Sequences
The synthesis of the capping agents 82 and 83 is shown in
FIG. 18. Commercially available maleic anhydride (80) is
condensed with 1-amino-3 -propanol to give 81, which will be
converted to the capping agents 82 and 83 under conditions
described earlier. The copolymerization agents 55 and 56 are
described earlier; 84-86 can be synthesized easily by one of
ordinary skill in the art. After synthesizing oligonucleotide on
solid support using standard phosphoramidite chemistry and
capping failure sequences with 82 (with activator such as
lFl-tetrazole) or 83 (with base such as Et3N), the crude oli
gonucleotide will be mixed with 55, 56 and 84 to incorporate
the failure sequences into polymer using reported conjugate
addition conditions. Alternatively, 84-86 may be used for
copolymerization.

30

35

40

45

50

Example 6
Synthesis of Capping Agents and Purification Via
Amide Bond Formation Reaction to Incorporate
Failure Sequences Into Polymer
The synthesis of the capping agent 141 is shown in FIG. 34.
After synthesizing oligonucleotide on solid support using
standard phosphoramidite chemistry and capping failure
sequences with 141 the crude oligonucleotide is not cleaved
or deprotected. The solid support is then directly treated with
copolymerization agent 145 at 60° C. for 12 hours. Then
cross-linking copolymerization agent 149 is added and the
mixture is thenheatedto about 90° C. for 6 hours. The failure
sequences and small molecules that resulted from deprotec
tion are now incorporated into polymer, while the full length

As shown in FIG. 19, the reaction between acetonitrile and
acetone produces 87, which is reduced to the amine 88. Com
pound 88 reacts with acryloyl chloride to produce 89 in the
presence of a base. The tertiary hydroxyl group in 89 is
silyatedwith 1 equivalent dichlorodiisopropylsilane followed
by addition of thymidine (suitably protected other nucleobases can also be used, but are not described in this proposal),
and this affords 90. The tertiary hydroxyl groups in 89 have
two advantages: they stabilize the diisopropylsilyl acetal link
age in 90, and they prevent dimer formation when 89 is mixed
with dichlorodiisopropylsilane. Compound 90 is phosphinylated with 91 to produce the target phosphoramidite 92 under
standard conditions. 5'-OFl oligonucleotide can be produced
using 92 for purification. 5'-phosphate oligonucleotides can
be purified using the phosphoramidite 95. Phosphoramidite
95 can be synthesized by reacting 89 with 1 equivalent dichlo
rodiisopropylsilane followed by addition of the commercially
available 93 to afford 94, which is phosphinylated to produce
95 under standard conditions (FIG. 19).
Oligonucleotides can be synthesized using a solid phase
synthesizer under standard conditions using phosphoramidite
methodology. At the end of synthesis, phosphoramidite 92 or
95 is coupled to the 5'-end of oligonucleotide on the synthe
sizer.
After deprotection and cleavage, oligonucleotide 96 (when
92 is used) or 97 (when 95 is used) is produced, along with
failure sequences and small organic impurities. The failure
sequences and impurities do not contain the acrylamide func
tionality. The crude oligonucleotide is then subjected to poly
merization conditions, such as acrylamide, N,N'-methylenebisacrylamide, (NFl4)2S20 8, TMEDA, r.t., 1 h. The full
length sequence 96 or 97 is incorporated into a polymer, and
the failure sequences and small organic impurities remain in
solution.
The failure sequences and small organic impurities can be
removed by filtration or extraction. The gel that contains the
full length sequence is washed with water, DMF and TF1F.
This is followed by treatment with fluoride ion (TBAF or
FIF/pyridine, r.t. FIG. 21) resulting in oligonucleotide 98 or
99. Oligonucleotide 98 is the target full length sequence with
5'-OH group. Oligonucleotide 99 can be treated with concen
trated methylamine to give oligonucleotide 100.
Example 8

55
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Synthesis of Phosphoramidites 103 and 105 and
Purification Via Disulfide Formation of Full-Length
Oligomers
Phosphoramidites 103 and 105 are synthesized according
to FIG. 22. The amino alcohol 88 is reacted with carboxylic
acid 37 (48 can also be used to give 101, which is coupled with
thymidine through the diisopropylsilyl acetal linker, and
phosphinylated to give phosphoramidite 103. For 5'-phosphate oligonucleotide synthesis, 101 is coupled with 93 using
the diisopropylsilyl acetal linker, and phosphinylated to
afford phosphoramidite 105. Using 103 or 105 as phosphora
midite in the last synthetic cycle in oligonucleotide synthesis,
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after deprotection/cleavage, the oligonucleotide has a struc
ture as shown by 106 or 107. Polymerization in the presence
of 44 and 45 incorporates 106 or 107 into polymer (see 108
and 109, FIG. 24). After removing failure sequences and
other impurities by filtration or extraction, oligonucleotides
98 or 100 are collected as described above (FIG. 24).

Example 12

5

Example 9
Synthesis of Phosphoramidites 113 and 115 and
Purification Via Sharpless “Click” Polymerization of
Full-Length Oligomers
Phosphoramidites 113 and 115 are synthesized according
to FIG. 25. The known alkyne 110 (can be synthesized from
inexpensive materials) is hydrolyzed, and coupled with 88 to
give 111, which is converted to the thymidine analog 112 and
phosphinylated to afford the phosphoramidite 113. The phosphoramidite 115 is synthesized from 111 and 93 in the same
way as described for the synthesis of 105. Using 113 or 115 as
phosphoramidite in the last synthetic cycle in oligonucleotide
synthesis, after deprotection and cleavage, the oligonucle
otide has a structure as shown by 116 or 117. Polymerization
in the presence of 65 and 66 incorporates 113 or 115 into
polymer (see 118 and 119, FIG. 27). After removing failure
sequences and other impurities by washing, oligonucleotides
98 or 100 is collected as described above.

10

The required phosphoramidites 122 and 124 are synthe
sized according to FIG. 28. Compound 70 is reacted with 88
to give 120, which is converted to the thymidine analog 121
and phosphinylated to afford the phosphoramidite 122. The
phosphoramidite 124 is synthesized from 120 and 93 in the
same way as described for the synthesis o f 105. Using 122 or
124 as phosphoramidite in the last synthetic cycle in oligo
nucleotide synthesis, after deprotection and cleavage, the oli
gonucleotide has a structure as shown by 125 or 126. Poly
merization in the presence of 78 incorporates 125 or 126 into
polymer (see 127 and 128, FIG. 30). After removing failure
sequences and other impurities, oligonucleotides 98 or 100
are collected as described above.
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Example 11
Synthesis of Phosphoramidites 132 and 134 and
Purification Via Conjugate Addition of Maleimide
and Thiol Full-Length Oligomers
The required phosphoramidites 132 and 134 are synthe
sized according to FIG. 31. Compound 129 (which can be
prepared from 3,5-diaminobenzoic acid and maleic anhy
dride) is reacted with 88 to give 130, which is converted to the
thymidine analog 131 and phosphinylated to afford the phos
phoramidite 132. The phosphoramidite 134 is synthesized
from 130 and 93 in the same way as described for the synthe
sis of 105. Using 132 or 134 as phosphoramidite in the last
synthetic cycle in oligonucleotide synthesis, after deprotec
tion and cleavage, the oligonucleotide has a structure as
shown by 135 or 136 (FIG. 32). Polymerization in the pres
ence of 84, 85 and 86 incorporates 135 or 136 into polymer
(see 137 and 138, FIG. 33). After removing failure sequences
and other impurities, oligonucleotides 98 or 100 are collected
as described above.

Phosphoramidite 150 is synthesized according to FIG. 35.
Using phosphoramidite 150 in the last synthetic cycle, the
oligonucleotide synthesized on the solid support has structure
152:
152

Example 10
Synthesis of Phosphoramidites 122 and 124 and
Purification Using Via Grubb’s Ring Opening
Metathasis Polymerization of Full-Length Oligomers

Synthesis of Phosphoramidites and Purification Via
Incorporation of Full Length Sequence into Polymer
using the Amide Bond Formation Reaction

50

Structure 152 is then treated with 146 at about 60° C. for
about 6 hours, without standard basic deprotection or cleav
age. During the reaction, the phenoxide in the full length
sequence is displaced by the amino group in 146. Next, the
cross-linking copolymerization reagent 149 is added and the
mixture heated to 90° C. for about 6 hours. During this reac
tion the oligonucleotides are cleaved from the solid support,
all protecting groups are removed, and the full length
sequence and the small molecules resulting from the protect
ing groups are incorporated into a polymerized material. Pure
full length sequence will be collected by treating with fluoride
as described above.
All patents, publications and references cited herein are
hereby fully incorporated by reference. In case of conflict
between the present disclosure and incorporated patents, pub
lications and references, the present disclosure should con
trol.
The invention claimed is:
1. A method of purifying an oligomer comprising:
capping any failure sequences produced during synthesis
with a capping agent haying a polymerizable functional
group;
polymerizing the capped failure sequences; and
separating the polymerized material from the full-length
oligomer;
wherein the capping agent is a compound of formula (IV):
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wherein R x is a halogen or a secondary amine;
R4 is
60
(CH2)t

t is an integer from 1 to 3.

